Signup/Login
If you want to receive notifications of upcoming IPOs, you need to simply sign up or sign in with social networks.
Signup/Login
Can you determine which companies are good and which ones - the trash?
Free Pro-version
IPO Filter
Monitor
IPO today
Upcoming IPO
Biofrontera (BFRI)
Marpai (MRAI)
Cingulate, Inc. (CING)
Stronghold Digital Mining, Inc. (SDIG)
Enfusion, Inc. (ENFN)
Portillos Inc. (PTLO)
Winc, Inc. (BEV)
The Vita Coco Company, Inc. (COCO)
P10, Inc. (PX)
Ventyx Biosciences, Inc. (VTYX)
Winc, Inc. (WBEV)
Runway Growth Finance Corp (RWAY)
Aris Water Solutions, Inc. (ARIS)
Minerva Surgical, Inc (UTRS)
Xilio Therapeutics, Inc. (XLO)
Informatica Inc. (INFA)
Arteris, Inc. (AIP)
Priced IPO
Mink Therapeutics, Inc. (INKT)
Paragon 28, Inc. (FNA)
Ihs Holding Limited (IHS)
Gitlab Inc. (GTLB)
Lucid Diagnostics, Inc. (LUCD)
Healthcare Triangle (HCTI)
AvidXchange (AVDX)
Cognition Therapeutics, Inc. (CGTX)
Isoplexis Corporation (ISO)
Pyxis Oncology, Inc. (PYXS)
Life Time Group Holdings, Inc. (LTH)
Theseus Pharmaceuticals, Inc. (THRX)
Tricon Residential (TCN)
Volcon (VLCN)
Nuvei (NVEI)
Tdcx, Inc. (TDCX)
First Watch Restaurant Group, Inc. (FWRG)
Exscientia Limited (EXAI)
Warby Parker (WRBY)
Olaplex Holdings Inc. (OLPX)
More companies

Dermata Therapeutics (DRMA)

Sector - Healthcare

Price chart

-35.71%
Return from IPO

Company News

IPO Profile

About company

They are a clinical-stage biotechnology company focusing on the treatment of medical and aesthetic skin conditions. Their lead product candidate, DMT310, is the first product candidate being developed from their Spongilla technology platform. DMT310 is of a once-weekly topical product derived from a naturally sourced freshwater sponge with multiple components. Based on DMT310’s multiple mechanisms of action, it is currently under clinical development for the treatment of acne vulgaris (or acne), psoriasis vulgaris (or psoriasis), and papulopustular rosacea (or rosacea). Their Spongilla technology platform is based on the use of a naturally growing freshwater sponge, Spongilla lacustris, or Spongilla. The Spongilla technology used in their product candidates, such as DMT310 and DMT410, comes from the unique chemical and mechanical components produced by Spongilla for its natural defense mechanisms. They recently received results from their Phase 2b clinical trial of DMT310 for the treatment of moderate-to-severe acne. The clinical endpoints used in the Phase 2b trial are identical to those endpoints they intend to use in their two Phase 3 acne clinical trials, which trials they believe will form the basis of their new drug application, or NDA, for DMT310.
Industry
Pharmaceutical Preparations
CEO CFO
-
Employees Founded
7 2014

Contacts

Address: 3525 Del Mar Heights Rd., #322 San Diego, Ca 92130

Telephone: (858) 800-2543

Web page: http://www.dermatarx.com

IPO information

First Trade Date 8/13/2021
Status Priced
Exchange NASDAQ
Lockup Period Expiration .Pro
Quiet Period Expiration .Pro
Old Price Range
-
Share prices ($)

Shares & Volumes

Shares Initial (MM) 1.9
Shares Revised (MM) 2.6
Expected offer amount (MM) $18
Realized offer amount(MM) $18.2

Financial Data (last reporting year)

Market Cap (MM) $57.49
Revenues (MM) $0
Net Income (Loss) (MM) $-4.1

Voting

What do you think will happen with the DRMA share price after the next 3-6 months? 🔥 (+ 10% or more, flat (+ -10%), -10% or less)

Number of votes: img
The lead left underwriter: Maxim Group LLC

IPOs led by the firm .Pro
Profitability of conducted IPOs  ?  .Pro
1st day change  ?  .Pro
Change for the first 3 months  ?  .Pro
Underwriters
Maxim Group LLC
CO-Managers
Brookline Capital Markets

Sector: Healthcare

Tweets about $DRMA

Tweets volume:

RT volume:

Timeframe:

Google Trends Stats